Author: Tiash Saha
Skin Cancers: The Sunny Challenge of Future (Potential Drugs and Treatments in Development)
KEY POINTS Ozone depletion, greenhouse gas-induced global warming, rising earth temperature is interacting to put a severe effect on human ...
Telemedicine a Blooming Area, Global Investments to Reach ~1 Billion in 2018: Medgenera Report
KEY POINTS About $725.9 million has been invested in telemedicine segment in 2017 by the global investors: Report Telemedicine is ...
Top Companies Leading the Rare Disease Drug Discovery (2018)
KEY POINTS Here are the six companies playing on the front foot in the segment of rare diseases drug discovery. ...
World’s 10 Top-Selling Orphan Drugs 2018
KEY POINTS Here are the 10 top-selling orphan drugs in terms of their worldwide sales in the previous financial year. ...
Roche’s New Drug Shows Better Results than Renowned Tamiflu in Flu Patients
Roche’s investigational flu drug, Xofluza® (baloxavir marboxil) has reduced the risk of complications in patients with flu in a late-stage clinical study. It is the first single-dose, oral drug being developed for flu with a novel mechanism of action in about the last 20 years.
Biogen’s Drug BAN2401 Brings in Fresh Hope for Alzheimer’s Treatment
Biogen/Eisai’s AD drug candidate, BAN2401 has shown positive results in a late-stage clinical study. This is the first late-stage anti-amyloid antibody (BAN2401) study to successfully achieve statistically significant results at 18 months. Login to read the full article.
[QUIZ] Healthcare Industry Knowledge Assessment
Healthcare Industry Knowledge Assessment How well do you know the healthcare industry? Take this assessment to identify your knowledge of ...
10 Potential Drugs in Development for Alzheimer’s Disease (2018)
KEY POINTS Here are the potential Alzheimer’s disease drug candidates in the late stage of clinical development in 2018. Companies ...
FDA Approves Best-Selling Drugs Combo, ‘Venclexta plus Rituxan’ to Treat Two Common Blood Cancers
Venclexta plus Rituxan combo reduced the risk of chronic lymphocytic leukemia (CLL) progression and death in patients by 81 percent compared to the standard-of-care regimen. It is the first oral-based, chemotherapy-free combination which provides an option of fixed treatment duration to CLL patients.
Mylan-Biocon Bags FDA Nod for Biosimilar Drug ‘Fulphila’, Reduces Infection Risk in Cancer Patients
US FDA approved Fulphila (pegfilgrastim-jmdb) – a biosimilar to Neulasta for reducing the chances of infection in patients with non-myeloid (non-bone marrow) cancer during chemotherapy. It is the first pegfilgrastim biosimilar that is approved by the US FDA.